Category: Monkey Pox Vaccine

There has been a spike in mpox infections in Toronto since the start of the year and public health officials are now warning eligible residents to make sure they are vaccinated.

The health unit says that since January there have been 21 confirmed cases of the virus in the city, compared to 27 in all of 2023.

In an interview CP24,Associate Medical Officer of Health Dr. Rita Shahin said that most of those who contracted mpox were not immunized against the virus.

"Of the 21 cases that we've seen since January 1, only three of them have had one dose of vaccine and the rest were unimmunized. So it's really an important reminder to people who are at risk that they should get their first dose and followed up with a second dose as well," she said.

"It is a small number of cases and we're not expecting to see the large number of cases that we saw in 2022 with over 500 cases. We know that many eligible people have gotten their first dose of vaccine, but not many came back for a second dose."

The best way to prevent mpox is through a two-dose vaccine that is given over a 28-day period, which protects those immunized against transmission as well as helps reduce serious symptoms of the virus. The vaccine becomes most effective after two weeks, TPS said.

Residents can find out more information about the vaccine, which is free of charge and accessible without an OHIP card, where they access sexual health care.

Shahin said TPH is sharing this latest information in an effort to raise awareness among those who are at the greatest risk of getting mpox and to urge them to get vaccinated.

Public health officials said that currently mpox is primarily being spread in the city between people who have had close/intimate or sexual contact with a person who has the virus. Those most affected include gay and bisexual men as well as men who have sex with other men, Toronto Public Health noted in a release.

"We want to remind cis and trans gay, bi, queer, and all men who have sex with men, to get their first and second dose of the mpox vaccine, Devan Nambiar, of Gay Mens Sexual Health Alliance, said in a release.

Mpox has not been entirely eradicated and we want you to take care of yourself and protect your sexual partners.

Public health officials went on to say that travel is not a significant factor among the current infections, meaning that the majority of the cases being seen in Toronto are the result of local community transmission.

Mpox, which is formerly known as monkeypox, is a virus that spreads from person to person through contact with infected lesions, skin blisters, body fluids, or respiratory secretions. It can also be transmitted through contact with contaminated materials like clothing or bedding as well as through bites or scratches from infected animals.

Symptoms of mpox can begin anywhere from five to 21 days after exposure and include fever, headache, muscle aches, exhaustion, and swollen lymph nodes. Toronto Public Health said that those symptoms are followed by a rash or blisters and lesions on the skin that can be painful, including around the genitals.

More information about mpox, including where to get vaccinated against it, can be found online.

Read the original:

Toronto Public Health reporting spike in mpox infections, residents urged to get vaccinated - CP24

Open this photo in gallery:

A Toronto public health official said she doesn't expect the uptick in mpox cases to lead to the same large outbreak that Canada saw in 2022, but urges people at risk of the virus to get vaccinated.Alain Jocard/The Associated Press

Toronto health officials are sounding the alarm about a rise in mpox cases and are urging anyone who may be at higher risk of contracting the virus to get vaccinated.

So far this year, there have been 21 confirmed cases of the virus, formerly known as monkeypox, in the city, compared with 27 cases in all of 2023.

Only two of this years confirmed mpox cases involved international travel, suggesting that local spread among unvaccinated or under-vaccinated individuals is contributing to the current situation, said Rita Shahin, associate medical officer of health with Toronto Public Health.

The mpox virus, explained: Symptoms, vaccines, spread and more

Mpox cases have been popping up in other jurisdictions, including Ottawa and New York, but less so in Montreal, Dr. Shahin said.

It does seem like theres still small pockets of local transmission in some areas, she said.

Mpox is predominantly spreading among men who have sex with men. People who have more than two sex partners, those who engage in anonymous sex or frequent sex clubs are at higher risk, Dr. Shahin said. The virus can spread person to person through contact with lesions, scabs or bodily fluids.

Mpox can lead to fever, muscle aches, a sore throat and a painful rash or lesions that can be on one part of the body, such as the face or genitals, or spread everywhere. Some individuals may experience serious complications, including bacterial infections, pneumonia, and brain or heart inflammation.

The viruss name was changed to mpox at the World Health Organizations suggestion, after a large outbreak in 2022 that was accompanied by racist and stigmatizing language about the infection.

Dr. Shahin said officials dont expect the uptick in mpox cases to lead to the same large outbreak that Canada saw in 2022, when Ontario reported nearly 700 cases. But she said its important for people who may be at risk to be aware of the situation and to protect themselves.

The mpox vaccine is a two-dose series given 28 days apart. During the 2022 outbreak, many higher risk people received one dose of the vaccine, but only 16 per cent received the second dose. Dr. Shahin said that could be because the outbreak began to wane, lessening the sense of urgency around vaccination.

An analysis published in the Cell journal last month credited a widespread change in behaviour among individuals with bringing the outbreak under control. At the time, vaccines werent readily available, but cases started to wane regardless, which the authors credit to public messaging to higher-risk individuals.

Dr. Shahin said that part of the reason there may be an increase in cases now is that individuals may be returning to higher-risk activities, such as having multiple sex partners.

Were not expecting to see a large outbreak, but its a good reminder for people to think about their sexual health and getting immunized if theyre eligible.

Continued here:

Rise in mpox virus cases prompts alert from Toronto public health officials - The Globe and Mail

DUBLIN, March 19, 2024 /PRNewswire/ -- The "Monkeypox Vaccine and Treatment Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2030" report has been added toResearchAndMarkets.com's offering.

The globalmonkeypox vaccine and treatment market was valued at USD 8.19 billion in 2022 and is expected to reach USD 19.68 billion in 2030, with a CAGR of 10.14% during the forecast period 2023-2030.

The report on the global monkeypox vaccine and treatment market provides qualitative and quantitative analysis for the period from 2021-2030. The study on monkeypox vaccine and treatment market covers the analysis of the leading geographies such as North America, Europe, Asia Pacific, and RoW for the period of 2021-2030.

The monkeypox vaccine and treatment market refer to the commercial landscape associated with products and services aimed at preventing and managing monkeypox infections. This includes the development, production, and distribution of vaccines and treatments designed to mitigate the impact of monkeypox outbreaks. Companies operating in this market focus on research, manufacturing, and strategic partnerships to provide effective solutions, addressing the demand for medical interventions in regions susceptible to monkeypox infections. The market plays a crucial role in public health by offering preventive measures and therapeutic options for individuals and communities affected by monkeypox.

The increasing incidence of monkeypox, accompanied by intermittent outbreaks, serves as a notable catalyst for the market. This heightened prevalence has created a demand for effective solutions and therapeutics, driving growth and innovation within the industry. As stakeholders seek to address the challenges posed by these outbreaks, opportunities for research, development, and market expansion are on the rise. The urgency to combat and manage monkeypox has propelled investment and initiatives, positioning the market to play a pivotal role in public health and safety.

The injectables segment stands out as the fastest-growing category in the monkeypox vaccine and treatment market. This notable growth is attributed to various factors such as the efficacy and rapid response associated with injectable formulations. As the demand for effective monkeypox prevention and treatment options rises, the injectables segment gains prominence due to its convenience, efficiency, and potential for widespread application. This trend underscores the increasing importance of injectable solutions in addressing the challenges posed by monkeypox, contributing significantly to the overall expansion and advancement of the market.

North America is poised to hold the most prominent market share. This prominence can be attributed to the region's robust healthcare infrastructure, advanced research capabilities, and strategic investments in the field of infectious disease management. The heightened awareness and proactive approach of North American healthcare authorities in addressing emerging health threats further contribute to this dominance.

Additionally, collaborations between pharmaceutical companies, research institutions, and government agencies in North America are fostering innovation and accelerating the development of effective monkeypox vaccines and treatments. The region's pivotal market position signifies lucrative opportunities for industry players and underscores its commitment to tackling public health challenges with cutting-edge solutions.

Report Findings

Drivers

Restraints

Opportunities

Company Profiles

The companies covered in the report include

Segment Covered

The Global Monkeypox Vaccine and Treatment Market by Product

The Global Monkeypox Vaccine and Treatment Market by Gender

The Global Monkeypox Vaccine and Treatment Market by Route of Administration

The Global Monkeypox Vaccine and Treatment Market by End-use

For more information about this report visit https://www.researchandmarkets.com/r/l8oifj

About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:

Research and Markets Laura Wood, Senior Manager [emailprotected]

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

SOURCE Research and Markets

More:

Global Monkeypox Vaccine and Treatment Analysis Report 2024: Market to Reach $19.68 Billion by 2030, Driven by ... - PR Newswire

More than 3,700 cases of mpox have been identified in the UK since May 2022

The National Institute for Health and Care Research (NIHR) has announced a new phase 1/2 trial, delivered by the NIHR Clinical Research Network and sponsored by Moderna, to test the effectiveness of an investigational mRNA vaccine for mpox.

The mPower trial will evaluate the safety and immune response to mRNA-1769, which aims to protect against illness caused by the mpox virus.

Currently a global public health threat, mpox is an infectious disease caused by the monkeypox virus, which is spread through physical contact with someone who is infected, leading to symptoms including painful rashes, enlarged lymph nodes and fever.

Since May 2022, over 3,700 cases of mpox have been identified in the UK, the majority of which have been from the Clade II B.1 lineage, predominantly in gay, bisexual and other men who have sex with men.

In the UK and Europe, there is only one vaccine licensed for the immunisation against mpox, called Imvanex, manufactured by Bavarian Nordic, along with Jynneos in the US and Imvamune in Canada.

Undertaken as part of the Moderna-UK Strategic Partnership, the trial aims to recruit around 350 healthy participants between the ages of 18 and 49 years old who have not been previously vaccinated for mpox and who have not had a suspected or confirmed mpox infection to receive the investigational vaccine or a placebo.

Researchers from University Hospitals Bristol and Weston NHS Foundation Trust are hoping to recruit a further 175 volunteers for the study, aiming to complete enrolment by April this year.

Dr Matthew Hallsworth, NIHR Director of Strategic Partnerships, said: Our partnership with Moderna ensures UK research is at the cutting edge of new vaccine technologies with the potential to protect against global health threats such as mpox and future pandemics.

We hope that recruitment to this trial will be as successful as the COVID-19 vaccine trials that were run in the UK and we encourage the public to help out where they can.

See original here:

NIHR reveals phase 1/2 trial to evaluate an investigational vaccine for mpox in the UK - PharmaTimes - PharmaTimes

Sign up for our free Health Check email to receive exclusive analysis on the week in health Get our free Health Check email

Volunteers are being sought to test a new mRNA vaccine for mpox, formerly known as monkeypox.

The vaccine trial from the National Institute for Health and Care Research (NIHR) and pharmaceutical firm Moderna will see whether the jab can offer good protection in people who have not been previously infected.

Mpox is passed on through close physical contact, including during sexual contact, kissing, cuddling or holding hands.

Symptoms include a high temperature, headache, muscle aches, backache, swollen glands, exhaustion, joint pain and a rash.

In the UK, one vaccine is currently licensed for immunisation against mpox.

Scientists now hope to offer another choice in the form of an mRNA jab for mpox and smallpox.

Volunteers in the mPower Trial will be randomly selected to receive one of three dose levels of the vaccine, or a placebo.

The trial is recruiting people from sites across the UK and will be led by the University Hospitals Bristol and Weston NHS Foundation Trust.

Dr Rajeka Lazarus, national co-ordinating investigator for the new study, said: Mpox is a global public health threat and more vaccines are urgently needed to prevent future outbreaks.

Throughout the Covid-19 pandemic, we were overwhelmed with the generosity of volunteers who came forward to take part in a number of vaccine trials.

Without them, the advances weve seen would not have been possible. It would be fantastic to see the same support for mpox research.

A health professional shows doses of Monkeypox vaccines

(AFP or licensors)

Experts are hoping to recruit 175 volunteers to the study, who are aged 18 to 49 and who are in good health, with plans to complete enrolment in April.

Volunteers must not have been previously vaccinated for mpox or smallpox, or had a suspected or confirmed mpox infection.

In 2022, there was an outbreak of monkeypox, with the UK reporting some of the highest case numbers in Europe, mostly in men who are gay, bisexual or have sex with other men.

The numbers have now dropped, with only 16 cases of mpox reported in England this year so far.

Dr Matthew Hallsworth, NIHR director of strategic partnerships, said: Were really pleased that Moderna has chosen to run its mpox trial in the UK. This demonstrates our strength in clinical research.

Our partnership with Moderna ensures UK research is at the cutting edge of new vaccine technologies, with the potential to protect against global health threats such as mpox and future pandemics.

We hope that recruitment to this trial will be as successful as the Covid-19 vaccine trials that were run in the UK and we encourage the public to help out where they can whether thats by volunteering or encouraging others.

Harun Tulunay, a 36-year-old sexual health advocate from London, suffered from the mpox virus in June 2022.

He ended up unable to eat or drink due to lesions in his throat. He was admitted to hospital and treated with an antiviral drug, which was originally developed for smallpox.

He said: As a man living with HIV, I took part in Covid trials and other trials to help other people.

People who will participate in this trial will be part of advancing research that will maybe change lives.

Being a part of that is such a great feeling I know that from my own experience.

People can find out more at trials.modernatx.com

More here:

Volunteers needed to test new mpox vaccine - The Independent

A new study into mpox has suggested that beyond gay and bi men getting the vaccine, people cutting back on their sexual partners played a major role in curbing the spread of the virus.

In 2022, cases of mpox (formerly known as monkeypox) exploded across Europe and the US. The disease is usually confined to parts of West and Central Africa. It soon became apparent that the virus was spreading predominantly between men who had sex with men.

Health authorities urged gay men to take advantage of an existing smallpox vaccine, which also limits the symptoms of mpox. Many queued up to obtain the vaccine. Its administered as two shots given a few weeks apart.

Subscribe to our daily newsletter for a refreshing cocktail (or mocktail) of LGBTQ+ entertainment and pop culture, served up with a side of eye-candy.

However, this new study found that viral spread began to decline before the vaccine roll-out had a big impact. Even before 10% of gay guys were vaccinated, mpox showed signs of peaking in the US.

They conclude that gay men temporarily reducing their number of sexual partners played a big role. It could be the main reason the mpox epidemic subsided as quickly as it did.

Once the mpox epidemic was recognized, behavioral modification in the men-who-have-sex-with-men community resulted in a sharp decline in [the rate of transmission] in North America ahead of vaccination rollout in the U.S., concluded a team led by Miguel Paredes, an epidemiologist at the Fred Hutchinson Cancer Center in Seattle.

The results appeared last week in the journal, Cell.

According to the CDC, in the US in 2022, there were 31,698 known cases of mpox and 56 deaths. The majority of deaths were in people who were immunocompromised, including those with HIV.

The outbreak was first reported in the UK in May 2022. Cases began to appear in the US later that month. It peaked in August 2022. Speaking to the New York Times, Paredes said this demonstrates that public health messaging can, be really powerful to control epidemics, even as were waiting for things like vaccines to come.

Those infected with mpox also develop a level of immunity from re-infection. Therefore, some high-risk individuals develop resistance without getting the vaccination.

The study used models, including flight data and genetic sequencing, to estimate when the outbreak occurred. They believe it likely started in the UK between December 2021 and March 2022, even if the first case wasnt diagnosed until May 2022.

They go on to say that the outbreak began spreading in five distinct global regions before health authorities became aware. Because of this, rushing to introduce travel bans would have had little impact.

Trevor Bedford, an evolutionary biologist at Fred Hutchinson Cancer Center in Seattle, said the research highlights the importance of closely monitoring viruses and bacteria within the community.

If we can catch emerging pathogens earlier on, like even weeks, it will make a big difference in terms of changing the course of these epidemics, Dr. Bedford told the New York Times.

Mpox has not disappeared and there are still cases popping up in the US. The CDC reports 312 cases so far in 2024. The states with the highest number of cases continue to be California and New York (34 and 77 cases so far in 2024 respectively). Both states were hotspots in 2022.

Doctors encourage all gay men to take advantage of the vaccine and to get both shots for maximum protection.

Read more here:

New study details how gay men helped curb the spread of mpox & stop the epidemic from getting worse - Queerty

Wake County Public Health is encouraging those at risk for mpox to get vaccinated and help prevent the spread by taking advantage of convenient, no-cost appointments and walk-in clinics.

This reminder comes on the heels of three new mpox cases confirmed in Wake County within the last six weeks.

The vaccine for mpox is widely available and is a safe, effective way to lower your risk of getting the virus, said Wake County Commissioner Cheryl Stallings. At Wake County, were making it as easy as possible for anyone who would like to receive the shot to do so. Getting the vaccine now can help protect you through spring and summer when large events and festivals tend to take place.

Mpox, formerly known as monkeypox, is a virus in the smallpox family. It first rose to the national spotlight in summer 2022 when there was an unusual global outbreak with more than 31,000 cases reported in the U.S. Since the beginning of the outbreak, 721 cases have been reported in North Carolina, with 119 of those being in Wake County.

Where to get vaccinated Wake County Public Health offers both walk-in and appointment services for the vaccine.

Walk-in services (no appointment needed):

Appointment only services:

The JYNNEOS vaccine is a two-dose injection that helps prevent against mpox when given before or shortly after exposure to mpox.

Mpox symptoms According to the CDC, symptoms of mpox can include:

In addition, those at risk of getting sick with mpox should consider taking the following safety precautions:

Learn more about mpox, including where to find testing and vaccinations, at wake.gov/mpox.

See the rest here:

Wake County Public Health reminds residents of free mpox vaccine offerings amid new cases - Wake County Government (.gov)

WAKE COUNTY, N.C. (WTVD) -- Wake County Public Health (WCPH) announced three new confirmed cases of mpox within the last six weeks.

Mpox is a virus in the smallpox family.

WCPH is now encouraging those at risk for the virus to get vaccinated.

They are now accepting walk-ins and appointments for the mpox vaccine.

The Centers for Disease Control voted to recommend routine mpox vaccines to prevent high-risk infections last October.

Back in 2022, the World Health Organization renamed monkeypox as 'mpox,' citing stigma and discrimination concerns.

See more here:

What is mpox | 3 new cases of mpox identified in Wake County - WTVD-TV

16/02/2024

Researchers are looking for volunteers to join its first-in-human vaccinations trial in the UK in the fight against monkeypox.

The North Wales Clinical Research Facility (NWCRF) are conducting the clinical trial sponsored by Moderna for investigational vaccines aimed at fighting mpox (previously known as monkeypox) and influenza.

The mpox study, called the mPower Trial, is helping researchers learn more about an investigational vaccine called mRNA-1769, that is being tested to see if it can preventillness from the mpox virus. The mPower Trial aims to study the safety profile and immune response to mRNA-1769.

The mPower Trial, being held at theNorth Wales Clinical Research Facility next to Wrexham Maelor Hospital, is currently enrolling adults between the ages of 18 and 49 who are in generally good health to take part in the investigational vaccine trial.

Dr Orod Osanlou, Director of NWCRF and Consultant in clinical pharmacology and therapeutics, internal medicine, said: Global viruses have the potential to change, causing hospitalisations and death around the world. Thats why its important to potentially prepare for outbreaks by studying investigational vaccines.

The research facility also has a database called Consent 4 Consent (C4C), an internal secure database of patients and volunteers who wish to be considered as potential participants for future research projects.

Dr Osanlou said: We are encouraging volunteers and patients to sign up to take part in our research projects. Nearly all research needs the help of volunteers in order to find out whether the investigational vaccines are safe and effective.

This is completely voluntary, you can choose to be removed from the database at any point. Some studies will also reimburse volunteers expenses for travel and inconvenience.

If youre interested in participating in either of these clinical trials, or wish to join the research trial database please contact the NWCRF research team via 03000 858032 or email BCU.NWCRFParticipant@wales.nhs.uk.

Read the rest here:

Wrexham Maelor researchers participate as investigators in a new UK first-in-human vaccination trial - Betsi Cadwaladr University Health Board

The CDCs Call for Increased JYNNEOS Vaccination

The Centers for Disease Control and Prevention (CDC) are urging clinicians, health departments, and community-based organizations to continue recommending the two-dose JYNNEOS vaccine to eligible individuals. Despite the vaccines availability at health clinics and pharmacies across the United States, the vaccination uptake has plateaued at just 25%. To protect public health and curb the spread of the virus, it is therefore essential that the uptake of the JYNNEOS vaccine is increased.

JYNNEOS, developed by Bavarian Nordic A/S, is a vaccine primarily used to protect against smallpox and monkeypox, collectively referred to as mpox. The JYNNEOS vaccine has been the subject of considerable investment by the U.S. government. Bavarian Nordic A/S secured $83 million in funding from the Biomedical Advanced Research and Development Authority (BARDA) for the vaccine, marking a second investment from the U.S. government. This brings the total investment into JYNNEOS to approximately $200 million, with an additional $12 million expected to be awarded in 2021. The funding will allow for the manufacturing of liquid-frozen doses of the vaccine and will improve preparedness against smallpox and monkeypox.

JYNNEOS is highly effective in preventing the spread of mpox. The vaccine has potential to protect against severe illness, hospitalization, and death. Numerous stories have been shared by individuals who have received the vaccine, providing first-hand accounts of its effectiveness and the importance of its widespread uptake. Not only does the vaccine protect the individual, but it also contributes to the overall health of the community by reducing the risk of spread.

Currently, there is an outbreak of mpox in the Democratic Republic of Congo (DRC). The CDC provides information about ways to reduce the risk of mpox during social gatherings and sexual activity, as well as self-care tips for those recovering from the virus. However, the most effective measure to prevent the spread of the virus is through vaccination. Therefore, the increased uptake of the JYNNEOS vaccine is crucial in containing the outbreak and protecting public health.

The JYNNEOS vaccine plays a vital role in preventing the spread of mpox and protecting against severe illness, hospitalization, and death. The CDCs call for increased vaccination rates, coupled with substantial investment from the U.S. government, underscores the importance of this vaccine. It is therefore crucial for individuals to get vaccinated and for health professionals to continue recommending the JYNNEOS vaccine. By doing so, we can protect not only ourselves but also our communities, and contribute to the global effort to curb the spread of mpox.

The rest is here:

CDC's Call for Increased JYNNEOS Vaccination | Vaccine Effectiveness and Outbreak Measures - Medriva